The primary function of an adverse reaction reporting system is to identify harmful effects associated with the use of medicines. Since 1964 the Australian system has contributed to the early recognition of many drug-related problems. Reports of suspected adverse drug reactions are sent to the Adverse Drug Reactions Unit of the Therapeutic Goods Administration by healthcare professionals, pharmaceutical companies and consumers. The reports are reviewed, coded and entered into a database before being analysed for patterns of adverse events. Selected reports are forwarded to the Adverse Drug Reactions Advisory Committee which can recommend actions ranging from no action to the withdrawal of a drug from the market. An important role of the Committee is to inform healthcare professionals about the adverse effects which emerge from their reports.
Introduction
In Australia, healthcare professionals, pharmaceutical companies and consumers can report suspected adverse drug reactions to the Adverse Drug Reactions Advisory Committee (ADRAC). Healthcare professionals usually submit reports on the 'blue card' which accompanies the Australian Adverse Drug Reactions Bulletin and the Schedule of Pharmaceutical Benefits.
Reports can also be made by letter, fax or electronically to http://www.tga.gov.au/problem/index.htm#medicines
Constant review of reports
Suspected adverse drug reactions are generally reviewed within three working days by staff in the Adverse Drug Reactions Unit of the Therapeutic Goods Administration. Selected reports are further reviewed by the independent medical experts of ADRAC.
Reports are searched for signals that may indicate safety issues.
Individual reports are reviewed and the proportional reporting ratio calculated for each reaction. This is the proportion of a specified reaction or group of reactions for a drug compared with the proportion for that reaction or group of reactions for all drugs in the database. 1 Health professionals should not defer making a report because a suspected association between an adverse event and a medicine has not previously been noted or seems tenuous. This would limit the ability of the system to detect new associations.
We are particularly interested in reports concerning newly marketed medicines because the safety information for these compounds is usually limited. We are also interested in reports concerning older medicines. The adverse event profile for these medicines may seem well-established, but new reactions, changes in the frequency of known adverse reactions, interactions or problems with generic forms of a medicine may occur and should be recognised to allow appropriate action to be taken.
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Analysis of aggregated reports

Strengths of spontaneous reporting
Spontaneous reporting systems are most valuable for identifying potential medication-induced adverse events when they are rare events unlikely to be associated with other causes. 2 The Australian voluntary reporting system differs from some overseas systems in that it accepts reports from consumers as well as from healthcare professionals and pharmaceutical companies. This is particularly important for over-the-counter and complementary medicines as the consumer may not have consulted a healthcare professional about the suspected reaction. an adverse event and a specific medication is suspected.
Limitations of spontaneous reporting
Recognition and reporting are least likely to occur when adverse events happen after prolonged treatment with a drug, when the condition reported is common in the community (for example hypertension) or it has other plausible aetiologies (for example diabetes). 2 An association between those types of adverse event and a medicine is more likely to be detected in case-control or cohort studies. In Australia we are not usually able to determine the total amount of a medication consumed. The voluntary reporting systems therefore cannot calculate the prevalence of adverse reactions.
Communication
The primary function of Australia's voluntary reporting system is to identify the risk of harm from drugs. Following from this 
